<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445221</url>
  </required_header>
  <id_info>
    <org_study_id>Immunonutrition</org_study_id>
    <nct_id>NCT03445221</nct_id>
  </id_info>
  <brief_title>Preoperative Immunonutrition and Cardiac Patients</brief_title>
  <official_title>Implication of Preoperative Immunonutrition Upon Cardiac Patients Undergoing Mitral Valve Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the progress of cardiac surgery, the indication of cardiac valve replacement has been&#xD;
      extended to include severely ill patients, even those with cardiac cachexia caused by&#xD;
      long-standing mitral valve disease. Since patients with advanced cardiac functional&#xD;
      disability are prone to fall into a low cardiac output state after valve replacement, Those&#xD;
      severely ill, cachectic patients may be susceptible to postoperative acute renal failure.&#xD;
      Preoperative malnutrition because of poor oral intake significantly increases the risk of&#xD;
      adverse events after surgery and leads to increased length of stay.&#xD;
&#xD;
      Major operation itself possibly cause the dysfunction of the host homeostasis, defense&#xD;
      mechanisms and inflammatory response, which would increase the rate of postoperative&#xD;
      complications and prolong hospital stay. Recently, many researchers argued that&#xD;
      immunonutritional formulas supplemented with biologically active nutrients were more&#xD;
      effective than standard nutrition intervention in improving inflammation, promoting the wound&#xD;
      healing and shortening the length of hospital stay (LOS) after operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility and type of the study: This randomized clinical trial will be conducted at Assiut&#xD;
      University Hospital from March 2018 until March 2019 after approval from the Institutional&#xD;
      Ethics Committee and after obtaining written informed consents from all cardiac patients&#xD;
      undergoing mitral valve replacement surgery.&#xD;
&#xD;
      Randomization and sample size :&#xD;
&#xD;
      Sample size calculation Sample size calculation was carried out using G*Power 3 software. A&#xD;
      calculated sample of 88 patients (44 cases and 44 controls) will be needed to detect an&#xD;
      effect size of 0.3 reduction in pro-BNP Level, with an error probability of 0.05 and 90%&#xD;
      power on a two-tailed test.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      Patients will be assigned into two equal groups of 44 patients each:&#xD;
&#xD;
      Group 1: patients will take preoperative immunonutrition in the form of intravenous glutamine&#xD;
      (Dipeptiven-Fersenius Kabi) 0.4 g/kg/day (once daily) for 5 days before surgery in addition&#xD;
      to a conventional diet.&#xD;
&#xD;
      Group 2: patients will continue conventional diet. Conventional median sternotomy will be&#xD;
      performed in all patients. Arterial line will be inserted. Anesthesia will be induced with&#xD;
      midazolam 0.05mg\kg, propofol 1-1.5mg\kg and fentanyl 2μg\kg. Anesthesia will be maintained&#xD;
      with isoflurane, fentanyl infusion1-2μ\kg\hr and Cis-atracurium infusion 2μ\kg\min before&#xD;
      cardiopulmonary bypass (CBP) and with propofol and fentanyl on CBP, according the&#xD;
      anaesthetist criteria. Anticoagulation will be achieved with heparin 3-4 mg\kg to maintain an&#xD;
      activated clotting time over 450s .Reversal of heparin will be with protamine.&#xD;
      Cardiopulmonary bypass will be achieved with a roller pump and a membrane oxygenator. After&#xD;
      the aortic clamp will be applied, asolution of 1000-1500 cc of hematic cardioplegia will be&#xD;
      administrated. Then 400-500 cc of solution will be administrated every 30min until the end of&#xD;
      the procedure. Mean arterial pressure should be above 60 mmHg for the duration of CBP.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      Cardiac function:&#xD;
&#xD;
        -  Preoperative and postoperative echocardiography.&#xD;
&#xD;
        -  Inotropic score every 2hours in first 6 hours then every 6 hours for the rest of 48&#xD;
           hours postoperatively.&#xD;
&#xD;
        -  Serum proBNP (Brain natruritic peptide) preoperatively and post operative first and&#xD;
           forth days.&#xD;
&#xD;
      Kidney function:&#xD;
&#xD;
        -  Urine output in the postoperative first and second days.&#xD;
&#xD;
        -  Serum urea and creatinine in postoperative first and second days.&#xD;
&#xD;
        -  Serum NGAL (Neutrophil gelatinase-associated lipocalin) preoperatively and postoperative&#xD;
           first and forth days.&#xD;
&#xD;
      Hemodynamics:&#xD;
&#xD;
      - MAP, HR every 2hours in first 6 hours then every 6 hours for the rest of 48 hours&#xD;
      postoperatively.&#xD;
&#xD;
      Hours of mechanical ventilation. Hospital and ICU stay. Any postoperative complications will&#xD;
      be recorded and treated.&#xD;
&#xD;
      Sampling:&#xD;
&#xD;
      Venous blood sample will be obtained by direct venipuncture and collected into serum&#xD;
      separator tubes. Samples will be centrifuged within 20 minutes from withdrawal and stored for&#xD;
      amixture of 12 hours at 2-8 ゜C before the separation of serum. Serum will be stored frozen at&#xD;
      -40 ゜C. Pro-BNP serum concentrations will be determined using an automated method.&#xD;
&#xD;
      Statistical analysis :&#xD;
&#xD;
      Data will be performed using a standard SPSS software package version 21 (SPSS Inc., Chicago,&#xD;
      Illinois, USA).Descriptive values will be expressed as mean ± SD, number or percentages. The&#xD;
      Student t-test will be used for comparison between means of variables and normally&#xD;
      distributed data. P will be considered significant if (p≤ 0.05).&#xD;
&#xD;
      Ethical Consideration:&#xD;
&#xD;
        -  The randomized clinical trial will be approved by local ethics committee of faculty of&#xD;
           medicine, Assiut University, Egypt after obtaining written informed consent from&#xD;
           patients.&#xD;
&#xD;
        -  There is no risk affecting the patients participating in this study.&#xD;
&#xD;
        -  Every patient can leave the study and will receive the same care.&#xD;
&#xD;
        -  Any data taken from all patient will be made confidential and available only to persons&#xD;
           conducting the study.&#xD;
&#xD;
        -  Any patient can stop participation in the study at any time without any loss of service.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Fuction</measure>
    <time_frame>4 days</time_frame>
    <description>Serum proBNP (Brain natruritic peptide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inotropic score</measure>
    <time_frame>4 days</time_frame>
    <description>Dopamine dose (mcg/kg/min) + Dobutamine dose (mcg/kg/min) + 100 x Epinephrine dose (mcg/kg/min) min 20 and max 60 The lower the inotropic score the better cardiac function and lower morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Function</measure>
    <time_frame>4 days</time_frame>
    <description>Serum NGAL (Neutrophil gelatinase-associated lipocalin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine output</measure>
    <time_frame>4 days</time_frame>
    <description>urine volume per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>2 days</time_frame>
    <description>mean arterial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Hospital Data</measure>
    <time_frame>4 days</time_frame>
    <description>Hospital and ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>4 days</time_frame>
    <description>any postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Cardiac Function</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will continue preoperative oral conventional diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IV Immunonutrition</intervention_name>
    <description>patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Conventional Diet</intervention_name>
    <description>patients will continue preoperative oral conventional diet.</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both sex&#xD;
&#xD;
          -  Age: 18-60 years.&#xD;
&#xD;
          -  Valvular heart disease .&#xD;
&#xD;
          -  ASA II,III&#xD;
&#xD;
          -  Non-diabetic.&#xD;
&#xD;
          -  Elective surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing renal disease(creatinine3.5mg/dl or dialysis)&#xD;
&#xD;
          -  Diabetic.&#xD;
&#xD;
          -  Off pump surgery.&#xD;
&#xD;
          -  Long CBP time &gt;120 min .&#xD;
&#xD;
          -  Previous cardiac surgery.&#xD;
&#xD;
          -  Hepatic failure or established cirrhosis.&#xD;
&#xD;
          -  Emergency surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaled M Morsy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant prof of anesthesia and intensive care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed F. Mostafa, MD</last_name>
    <phone>01001123062</phone>
    <phone_ext>002</phone_ext>
    <email>mo7_fathy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramy MA Mohammed, MCs</last_name>
    <phone>01019958281</phone>
    <phone_ext>002</phone_ext>
    <email>ramymostafa888@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOHAMED F MOSTAFA, ND</last_name>
      <phone>01001123062</phone>
      <phone_ext>002</phone_ext>
      <email>mo7_fathy@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>HAMDY A YOUSSEF, MD</last_name>
      <phone>01090008490</phone>
      <phone_ext>002</phone_ext>
      <email>hamdyayoussef@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>October 25, 2020</last_update_submitted>
  <last_update_submitted_qc>October 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed F. Mostafa</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Oral Immunonutrition</keyword>
  <keyword>Cardiac Patient</keyword>
  <keyword>Mitral Valve Replacement</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

